ImpriMed

ImpriMed is a leading precision medicine startup that is revolutionizing cancer treatment with artificial intelligence. The company’s groundbreaking drug response prediction technology helps reduce costs, accelerate treatment, improve efficacy, and enhance patients’ quality of life. So far, the company’s technology has been deployed across more than 40 states in the U.S., and as of 2023, it has conducted over 15,000 blood tests for canine and feline cancer. ImpriMed is now preparing to expand its pioneering AI-driven approach into human healthcare, redefining the future of oncology treatment with personalized and effective solutions.